Cold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial
Necrosis After Cold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Prospective Randomized Controlled Trial
1 other identifier
interventional
566
1 country
1
Brief Summary
The purpose of this study is to analyze whether cold dissection can decrease the rate of ischemia necrosis and other complications and then increase the aesthetic outcomes compared to electrocautery. The purpose of this study is to analyze whether cold dissection can decrease the rate of ischemia necrosis and other complications and then increase the aesthetic outcomes compared to electrocautery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 23, 2022
CompletedFirst Submitted
Initial submission to the registry
November 30, 2022
CompletedFirst Posted
Study publicly available on registry
September 6, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
February 13, 2025
February 1, 2025
4.1 years
November 30, 2022
February 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Necrosis complications within one month post operation
Necrosis complications included nipple-areolar complex (NAC) and skin flap necrosis. NAC/skin flap necrosis could present as minor superficial epidermolysis requiring local wound care only, or full-thickness necrosis with any exposure of acellular dermal matrix, muscle, implant, or with full-thickness eschar that required surgical reoperation of debridement and repair.
Within one month post operation
Secondary Outcomes (12)
Necrotic complications within 1 year post operation
Within 1 year post operation
Surgical-site infection rate(SSI)
within one year post operation
The incidence of postoperative complications
within one year post operation
Cosmetic outcomes evaluated by 5-point Likert Scale
Evaluated pre-operation, at the first month, at 2 months, 3 months, 6 months and 12 months.
Patient-reported outcomes (as measured using the BREAST-Q score)
Evaluated pre-operation, at the first month, at 2 months, 3 months, 6 months and 12 months.
- +7 more secondary outcomes
Study Arms (2)
Cold Dissection
EXPERIMENTALIn this group, the septa between the skin flap and parenchyma was dissected using with scissors or scalpel
Electrocautery Dissection
ACTIVE COMPARATORIn this group, the septa between the skin flap and parenchyma was dissected using with electrocautery
Interventions
The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.
The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.
Eligibility Criteria
You may qualify if:
- Tumor smaller than 5 cm
- No evidence of NAC, skin or chest wall invasion.
You may not qualify if:
- Patients with apparent NAC involvement, chest wall or skin invasion, inflammatory breast cancer, locally advanced breast cancer or severe comorbid conditions or poor performance status assessed by the primary physicians, such as heart disease, renal failure, liver dysfunction, and poor performance status as assessed by the primary physicians.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shicheng Su
Guangzhou, Guangdong, 510120, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shicheng Su
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 30, 2022
First Posted
September 6, 2023
Study Start
November 23, 2022
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
February 13, 2025
Record last verified: 2025-02